Lineage Cell Therapeutics
LCTX
Market cap $93.9M

0.4110 USD

-0.0406

8.99%

At close Apr 1, 4:00 PM EDT

After hours

0.4200

+0.0090

2.19%

1 day

-8.99%

5 days

-20.98%

1 month

-19.43%

3 months

-20.19%

6 months

-54.09%

Year to date

-20.19%

1 year

-71.85%

5 years

-42.92%

10 years

-54.74%

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 7,398 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

131% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 16

108% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 13

9% more funds holding

Funds holding: 114 [Q3] → 124 (+10) [Q4]

1.86% less ownership

Funds ownership: 50.44% [Q3] → 48.58% (-1.86%) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

38% less capital invested

Capital invested by funds: $86.2M [Q3] → $53.8M (-$32.4M) [Q4]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$2

387%

upside

Avg. target

$4.25

934%

upside

High target

$9

2,090%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

B. Riley Securities Mayank Mamtani 14% 1-year accuracy 3 / 22 met price target	630%upside $3	Buy Maintained	14 Mar 2025
D. Boral Capital Jason Kolbert 30% 1-year accuracy 99 / 328 met price target	387%upside $2	Buy Maintained	11 Mar 2025
HC Wainwright & Co. Joseph Pantginis 20% 1-year accuracy 85 / 420 met price target	2,090%upside $9	Buy Reiterated	11 Mar 2025
Maxim Group Michael Okunewitch 13% 1-year accuracy 1 / 8 met price target	630%upside $3	Buy Maintained	10 Jan 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about LCTX published over the past 30 days

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript

Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Conference Call Participants Jack Allen - Baird Joseph Pantginis - H.C. Wainwright Michael Okunewitch - Maxim Group Mayank Mamtani - Riley Securities Albert Lowe - Craig-Hallum Sean McCutcheon - Raymond James Operator Thank you for standing by.

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today reported its fourth quarter and full year 2024 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. “Throughout 2024, we made substantial progress across multiple fronts, advancing o.

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m.

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, announced today that the Company has initiated the DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study. The DOSED study will evaluate the safety and utility of the Manual Inject Parenchymal Spinal Delivery Syste.

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that Brian M. Culley, Lineage's Chief Executive Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Lifesciences Conference on February 11, 2025 at 12:40pm ET. The conference is being held virtually February 11-12, 2025. Interested parties can view a re.

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

24/7 Wall Street

Insiders Are Scooping Up These 5 Stocks Now

Since the beginning of the year, the number of notable insider purchases has been lower than usual.

Insiders Are Scooping Up These 5 Stocks Now

Zacks Investment Research

Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Lineage Cell (LCTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its previously announced registered direct offering of an aggregate of up to $66 million. The Company had previously received $24 million in gross proceeds at the closing of the first tranche in November 2024. Today, the Company received an addit.

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

Lineage Cell Therapeutics Issues Letter to Stockholders

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to shareholders highlighting the company's recent achievements and outlook for 2025. Dear Fellow Shareholders, We hope you had a restful holiday season and wish you a happy new year. As we look at our plans for the new year, we want to update you on our recent progress and.

Lineage Cell Therapeutics Issues Letter to Stockholders

Zacks Investment Research

Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Lineage Cell (LCTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround

See News Rankings

Charts implemented using Lightweight Charts™